Literature DB >> 2081972

Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction.

L N Shih1, J C Sheu, J T Wang, G T Huang, P M Yang, H S Lee, J L Sung, T H Wang, D S Chen.   

Abstract

Serum hepatitis B virus (HBV) DNA was assayed using polymerase chain reaction, in 107 HBsAg-negative normal Chinese subjects. The results showed that eight subjects (7.5%) had HBV DNA. In the subgroup with antibody to hepatitis B surface antigen (anti-HBs) and to hepatitis B core antigen (anti-HBc), 7.3% (5/68) were positive for HBV DNA; HBV DNA was not detected in six individuals with anti-HBs only and in nine with anti-HBc only. In four persons with anti-HBc and anti-HBe, one had HBV DNA. In 20 subjects negative for all hepatitis B serological markers, two (10%) were found to have HBV DNA. This study indicates that serological markers are not adequate to rule out HBV infection, and it further implies that present blood donor screening methods may need improving.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081972     DOI: 10.1002/jmv.1890320412

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

2.  Improved detection of hepatitis B virus surface antigen by a new rapid automated assay.

Authors:  B Weber; A Bayer; P Kirch; V Schlüter; D Schlieper; W Melchior
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 3.  Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants.

Authors:  Hong Kim; Bum-Joon Kim
Journal:  Int J Mol Sci       Date:  2015-06-15       Impact factor: 5.923

4.  Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.

Authors:  Kai-Lin Chen; Jie Chen; Hui-Lan Rao; Ying Guo; Hui-Qiang Huang; Liang Zhang; Jian-Yong Shao; Tong-Yu Lin; Wen-Qi Jiang; De-Hui Zou; Li-Yang Hu; Michael Lucas Wirian; Qing-Qing Cai
Journal:  Chin J Cancer       Date:  2015-05-28

5.  The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.

Authors:  Qingqing Cai; Kailin Chen; Jie Chen; Shaoxu Wu; Qirong Geng; Huiqiang Huang; Tongyu Lin; Wenqi Jiang; Zhongjun Xia; Huaxin Duan; Huilan Rao; Mengfei Yao; Liyang Hu
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.